Abstract
Systemic lupus erythematosus (SLE) is increasingly being recognized among the elderly. The so-called late-onset lupus seems to conform a quite defined patient subgroup with a frequency that ranges from 4–18% in different studies. According to several authors, late-onset lupus patients tend to have less of a female predominance. More insidious and less defined disease manifestations among this patient population may turn the diagnosis into a clinical challenge; therefore, many other diagnoses need to be excluded. It has been suggested that late-onset patients have a more benign disease course as they usually have less major organ system involvement, fewer clinical relapses, and lower degrees of disease activity. Mucocutaneous, renal, and neurological involvement has been reported to be less frequent among these patients. Treatment modalities have not been specifically studied in this patient subgroup; pharmacological interventions need to be tailored not only to the clinical manifestations of the disease, but also to the presence of other comorbidities and the drugs’ safety profiles. Despite this apparent benign course, patients whose disease begins later in life may not have such a good prognosis in terms of survival. It is possible that these patients’ poor long-term outcomes result from the impact SLE, along with other comorbidities, has in this older patient population.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56(9):1–39.
Keating N, Fox WT. Editorial: longevity health and well-being. Issues in aging in North America. J Nutr Health Aging. 2008;12(2):99–100.
Taylor K, Chung S, Graham R, Ortmann W, Lee A, Langefeld C et al. Genetic risk score for systemic lupus erythematosus is associated with age of onset and autoantibody production [abstract/program 1873]. Presented at the 59th Annual Meeting of The American Society of Human Genetics, Honolulu, Hawaii. 2009. http://www.ashg.org/2009meeting/abstracts/fulltext/.
Catoggio LJ, Skinner RP, Smith G, Maddison PJ. Systemic lupus erythematosus in the elderly: clinical and serological characteristics. J Rheumatol. 1984;11(2):175–81.
Mak SK, Lam EK, Wong AK. Clinical profile of patients with late-onset SLE: not a benign subgroup. Lupus. 1998;7(1):23–8.
Font J, Pallares L, Cervera R, Lopez-Soto A, Navarro M, Bosch X, et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis. 1991;50:702–5.
Voulgari PV, Katsimbri P, Alamanos Y, Drosos AA. Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. Lupus. 2002;11(11):722–9.
Rovensky J, Tuchynova A. Systemic lupus erythematosus in the elderly. Autoimmun Rev. 2008;7(3):235–9.
Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum. 1989;32(10):1226–32.
Boddaert J, Huong DL, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83(6):348–59.
Maddison P, Farewell V, Isenberg D, Aranow C, Bae S, Barr S, et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol. 2002;29(5):913–7.
Bertoli AM, Alarcon GS, Calvo-Alen J, Fernandez M, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum. 2006;54(5):1580–7.
Baker SB, Rovira JR, Campion EW, Mills JA. Late onset systemic lupus erythematosus. Am J Med. 1979;66:727–32.
Costallat LT, Coimbra AMV. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol. 1994;12(6):603–7.
Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, Pujol R. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. SLE Disease Activity Index. Lupus. 1999;8(6):462–5.
Shaikh SK, Wang F. Late-onset systemic lupus erythematosus: clinical and immunological characteristics. Med J Malaysia. 1995;50(1):25–31.
Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term survival of Southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore). 2005;84(4):218–24.
Lalani S, Pope J, de Leon F, Peschken C. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1,000 faces of lupus study. J Rheumatol. 2010;37(1):38–44.
Dimant J, Ginzler EM, Schlesinger M, Diamond HS, Kaplan D. Systemic lupus erythematosus in the older age group: computer analysis. J Am Geriatr Soc. 1979;27(2):58–61.
Appenzeller S, Pereira DA, Costallat LTL. Greater accrual damage in late-onset systemic lupus erythematosus: a long-term follow-up study. Lupus. 2008;17(11):1023–8.
Pu SJ, Luo SF, Wu YJ, Cheng HS, Ho HH. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus. 2000;9(2):96–100.
Ho CT, Mok CC, Lau CS, Wong RW. Late onset systemic lupus erythematosus in Southern Chinese. Ann Rheum Dis. 1998;57(7):437–40.
Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus. 2007;16(1):28–34.
Sayarlioglu M, Cefle A, Kamali S, Gul A, Inanc M, Ocal L, et al. Characteristics of patients with late onset systemic lupus erythematosus in Turkey. Int J Clin Pract. 2005;59(2):183–7.
Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166–82.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus. Difference related to race and age of onset. Arthritis Rheum. 1982;25:55–60.
Koh ET, Boey ML. Late onset lupus: a clinical and immunological study in a predominantly Chinese population. J Rheumatol. 1994;21(8):1463–7.
Wilson HA, Hamilton ME, Spyker DA, Brunner CM, O’Brien WM, Davis JS, et al. Age influences the clinical and serologic expression of systemic lupus erythematosus. Arthritis Rheum. 1981;24(10):1230–5.
Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients, with emphasis on demographic subsets. Medicine. 1985;64:285–95.
Gossat DM, Walls RS. Systemic lupus erythematosus in later life. Med J Aust. 1982;1(7):297–9.
McDonald K, Hutchinson M, Bresnihan B. The frequent occurrence of neurological disease in patients with late-onset systemic lupus erythematosus. Br J Rheumatol. 1984;23(3):186–9.
Takayasu V, Bonfa E, Levy NM, Kumeda C, Daud RM, Cossermelli W. Systemic lupus erythematosus in the aged: clinical and laboratory characteristics. Rev Hosp Clin Fac Med Sao Paulo. 1992;47(1):6–9.
Padovan M, Govoni M, Castellino G, Rizzo N, Fotinidi M, Trotta F. Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int. 2007;27(8):735–41.
Maddison PJ. Systemic lupus erythematosus in the elderly. J Rheumatol. 1987;14 Suppl 13:182–7.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113–24.
Domenech I, Aydintug O, Cervera R, Khamashta M, Jedryka-Goral A, Vianna JL, et al. Systemic lupus erythematosus in 50 year olds. Postgrad Med J. 1992;68(800):440–4.
Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270–80.
Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, et al. Sjogren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren’s syndrome. Arthritis Rheum. 2004;50(3):882–91.
Maddison PJ. Is it SLE? Best Pract Res Clin Rheumatol. 2002;16(2):167–80.
Finks SW, Finks AL, Self TH. Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South Med J. 2006;99(1):18–22.
Carter JD, Valeriano-Marcet J, Kanik KS, Vasey FB. Antinuclear antibody-negative, drug-induced lupus caused by lisinopril. South Med J. 2001;94(11):1122–3.
Morrow JD, Schroeder HA, Perry Jr HM. Studies on the control of hypertension by hyphex. II. Toxic reactions and side effects. Circulation. 1953;8(6):829–39.
Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol. 1999;11(5):357–63.
Atzeni F, Marrazza MG, Sarzi-Puttini P, Carrabba M. Drug-induced lupus erythematosus. Reumatismo. 2003;55(3):147–54.
McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633–44.
Langford RM. Pain management today – what have we learned? Clin Rheumatol. 2006;25 Suppl 1:S2–8.
Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280–7.
American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 Update. Arthritis Rheum. 2001;44:1496–503.
Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80–5.
Fessler BJ, Alarcon GS, McGwin Jr G, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–80.
Alarcon GS, McGwin Jr G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. Data from LUMINA, a multiethnic us cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168–72.
van Lankveld W, Franssen M, Stenger A. Gerontorheumatology: the challenge to meet health-care demands for the elderly with musculoskeletal conditions. Rheumatology. 2005;44(4):419–22.
Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Lupus. 2000;9:322–7.
Strand V. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Lupus. 2004;13(5):406–11.
Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107–18.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40.
Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447–58.
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000;27:373–6.
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger Jr TA, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145:408–15.
Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 2002;61(12):1064–70.
Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol. 1997;24:1061–5.
Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol. 2002;29(7):1398–400.
Acknowledgments
The work of Drs. Guillermo Pons-Estel and Paula Burgos was supported by a Supporting Training Efforts in Lupus for Latin American Rheumatologists (STELLAR) award funded by Rheuminations, Inc.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bertoli, A.M., Pons-Estel, G.J., Burgos, P.I., Alarcón, G.S. (2011). Systemic Lupus Erythematosus in Elderly Populations. In: Nakasato, Y., Yung, R. (eds) Geriatric Rheumatology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5792-4_15
Download citation
DOI: https://doi.org/10.1007/978-1-4419-5792-4_15
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-5791-7
Online ISBN: 978-1-4419-5792-4
eBook Packages: MedicineMedicine (R0)